The Impact of Obesity on Inflammatory Bowel Disease
Open Access
- 8 December 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3256
Abstract
Obesity is prevalent in the inflammatory bowel disease (IBD) population, particularly in newly developed countries where both IBD and obesity in the general population are on the rise. The role of obesity in the pathogenesis of IBD was entertained but results from available studies are conflicting. It does, however, appear to negatively influence disease course whilst impacting on our medical and surgical therapies. The pro-inflammatory profile of the visceral adipose tissue might play a role in the pathogenesis and course of Crohn’s Disease (CD). Interestingly, isolating the mesentery from the surgical anastomosis using a KONO-S technique significantly decreases anastomotic recurrence rate. Anti-obesity therapy is not widely used in IBD but was suggested as an adjunctive therapy in those patients. In this review, we aimed to highlight the epidemiology of obesity in IBD and to describe its influence on disease course and outcomes.Keywords
This publication has 91 references indexed in Scilit:
- Repeat Intestinal Resections Increase the Risk of Recurrence of Crohn's DiseaseDiseases of the Colon & Rectum, 2013
- Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patientsAlimentary Pharmacology & Therapeutics, 2011
- Stoma Issues in the Obese PatientClinics in Colon and Rectal Surgery, 2011
- Inflammatory Bowel Disease in the Obese PatientClinics in Colon and Rectal Surgery, 2011
- Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease 12Inflammatory Bowel Diseases, 2011
- Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's diseaseGut, 2011
- Bariatric surgery in inflammatory bowel diseaseTidsskrift for Den norske legeforening, 2010
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel DiseasesGastroenterology Clinics of North America, 2006
- Mesenteric fat in Crohn’s disease: a pathogenetic hallmark or an innocent bystander?Gut, 2006